Aaron Levitt

InvestorPlace Contributor

Aaron Levitt is an independent investment analyst and author living in State College, Pennsylvania. His work appears in several high profile publications in both print and on the web.

As an advocate for long-term globally oriented investing, Aaron believes that exchange traded funds have leveled playing field for Main Street. Following global macro-economic trends, investors now have several avenues to create great long term portfolios.

Aaron is a graduate of The Pennsylvania State University where he studied Economics and International Business. Aside for helping regular investors develop winning portfolios, his current projects include writing his first book on alternative energy investing.

Follow his picks and pans on Twitter at @AaronLevitt.

Recent Articles

Williams-Sonoma, Inc. Stock Is Still Amazon Proof

By Aaron Levitt, InvestorPlace Contributor Mar 29, 2018

A high-end customer base is keeping Williams-Sonoma cooking. That should continue with higher online sales and tech initiatives, which will bolster WSM stock.

3 Reasons You Should Stay Away from Chevron Corporation Stock

By Aaron Levitt, InvestorPlace Contributor Mar 27, 2018

Is Chevron a big buy or big sell? We take a look at 3 pros and 3 cons facing CVX stock investors.

5 Gold Stocks to Buy Today

By Aaron Levitt, InvestorPlace Contributor Mar 26, 2018

Given the market's shake-up, gold stocks have plenty of appeal. Here are five for alert investors to buy today.

‘Tech Dinosaur’ Seagate Technologies PLC Is Crushing It

By Aaron Levitt, InvestorPlace Contributor Mar 26, 2018

Seagate Technologies may have once been considered a tech dinosaur but it's quickly becoming a player in hot tech trends like big data, the Internet of Things, mobile apps and blockchain. And yet Seagate stock is still trading like it was a tech castaway. For investors, STX could be a huge steal.

5 Big Biotech Stocks to Buy Under $10

By Aaron Levitt, InvestorPlace Contributor Mar 20, 2018

Small biotech stocks can pack a wallop. Here are five biotech stocks that have prospects bigger than their share prices.